Attributable mortality and Costs of Invasive Candida Infections in European hospitals

The European Confederation of Medical Mycology (ECMM) conducts studies on invasive Candidiasis (IC) in Europe in 10-year intervals. Thus, we will conduct the third multicentre ECMM study on nosocomial IC in Europe, CANDIDA III in 2018.
The title of the study will be “Attributable mortality and Costs of Invasive Candida Infections in European hospitals: a prospective case-control study”, and the study as well as the working group will be lead by PD Martin Hoenigl and Prof. Oliver Cornely. The case-control study will focus on evaluating attributable mortality and costs as well as diagnostic and therapeutic approaches (including prolonged hospital stay for completion of parenteral antifungal treatment) of nosocomial IC infections in Europe. As a secondary objective we will evaluate antifungal resistance among Candida spp. causing invasive diseases across Europe. In addition, the case control design will allow for implementation of health economic analyses on the incremental costs associated with IC infections.
The study will include first 10 adult patients with candidemia defined according to ECMM/ESCMID criteria, i.e. at least one blood culture positive blood sample. Participating hospitals are required to include one matched control for each case with candidemia.
For enrolment, the study will allow for a maximum 8 hospitals per ECMM member country, depending on the population size. Up to a maximum of 8 hospitals for the 6 ECMM countries with populations >50 million (i.e. Russia, Germany, Turkey, France, UK and Italy; mean population of these countries is 82.5 million), up to a maximum of 4 hospitals for ECMM countries with population >25 million and <50 million (i.e. Spain and Poland; mean population of these countries 42 million), and up to 2 hospitals for the remaining 16 ECMM countries with population <25 million (mean population 9.4 million). Maximum total study population is therefore 880 cases and 880 controls.